220616-11-5

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Imidazolidinedione, 3-[(2S)-2-(hydroxyamino)-3-[[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]oxy] propyl]-5,5-dimethylis used as a pharmaceutical agent for its potential role in the development of new drugs. 2,4-Imidazolidinedione,
3-[(2S)-2-(hydroxyamino)-3-[[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]oxy]
propyl]-5,5-dimethyl-'s unique structure, including the heterocyclic ring and functional groups, may allow it to interact with biological targets in ways that could lead to therapeutic benefits. Its specific application may be determined by further research into its biochemical properties and interactions with biological systems.
Used in Materials Science:
In the field of materials science, 2,4-Imidazolidinedione, 3-[(2S)-2-(hydroxyamino)-3-[[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]oxy] propyl]-5,5-dimethylmay be utilized for the creation of novel materials with specific properties. 2,4-Imidazolidinedione,
3-[(2S)-2-(hydroxyamino)-3-[[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]oxy]
propyl]-5,5-dimethyl-'s structural features could contribute to the development of materials with tailored characteristics, such as improved stability, reactivity, or selectivity in various chemical processes. Its application in this field would depend on ongoing research into its material properties and potential integration into existing or new material systems.

Upstream product

• 364731-97-5 C₃₁H₃₈F₃N₃O₉ 
• 139301-27-2 4-trifluoromethoxyphenylboronic acid 
• 361547-40-2 3-[(2S)-3-(4-bromophenoxy)-2-(hydroxyamino)propyl]-5,5-dimethyl-1,3-diazolidine-2,4-dione 
• 220616-06-8 C₃₃H₃₈F₃NO₈ 
• 220616-04-6 (R)-1-Benzyloxy-3-(4'-trifluoromethoxy-biphenyl-4-yloxy)-propan-2-ol 
• 173025-79-1 4-(4'-trifluoromethoxy phenyl)-phenol 
• 777063-53-3 4-methoxy-4′-(trifluoromethoxy)-1,1′-biphenyl 
• 5720-07-0 4-methoxyphenylboronic acid 
• 407-14-7 1-bromo-4-(trifluoromethoxy)benzene 
• 365572-70-9 3-{(3E)(2S)-3-aza-2-[(4-bromophenyl)methyl]-4-(4-methoxyphenyl)but-3-enyl}-5,5-dimethyl-1,3-diazolidine-2,4-dione 
• 365572-69-6 (3E)(2S)-3-aza-2-[(4-bromophenyl)methyl]-4-(4-methoxyphenyl)but-3-en-1-ol 
• 365572-61-8 (4R)-4-[(4-bromophenoxy)methyl]-1,3-oxazolidin-2-one 
• 365572-68-5 (2S)-2-amino-3-(4-bromophenoxy)propan-1-ol 
• 106-41-2 4-bromo-phenol 

Relevant academic research and scientific papers

Synthesis of [14C]ABT-770, matrix metalloproteinase inhibitor (MMPI), labelled in the phenoxy ring

The MMPI [14C]ABT-770 (1), N-[(1S)-1-[(4,4-Dimethyl-2,5-dioxo-1-imidazolidinyl)methyl]]-2-[[4′ -(trifluoromethoxy)[1,1′-biphenyl]-4-yl]oxy]ethyl]-N-hydroxyformamide was synthesized in 8 steps using 4-bromophenol-UL-14C (10) as a star

Process for the selective N-formylation of N-hydroxylamines

The instant invention provides a process for the selective N-formylation of N-hydroxylamines.

Process for the preparation of matrix metalloproteinase inhibitors

The instant invention provides a process for the synthesis of matrix metalloproteinase inhibitors.

Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770

Modification of the biphenyl portion of MMP inhibitor 2a gave analogue 2i which is greater than 1000-fold selective against MMP-2 versus MMP-1. The stereospecific synthesis of both enantiomers of 2i was achieved beginning with (S)- or (R)-benzyl glycidyl ether. The (S)-enantiomer, 11 (ABT-770), is orally bioavailable and efficacious in an in vivo model of tumor growth. Elsevier Science Ltd. All rights reserved.